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Abstract
In this article the role of molecular imaging with SPECT and
PET in patients with movement disorders is reviewed. It is men-
tioned that SPECT and PET imaging with cocaine analogues
(123I-b-CIT,123I-FP-CIT, 18F-DOPA), radioligands labeling the pre-
synaptic dopamine transporters, is of value for the differentia-
tion of patients with PD or Parkinson-plus syndromes with indi-
viduals with essential tremor. In addition the clinical impact of
this procedure, the role of molecular imaging in the preclinical
diagnosis and in the follow-up of patients with PD, as well as, in
the differential diagnosis between Alzheimers disease and
Lewy-body dementia, is evaluated. Finally, the clinical impact
of 123I-IBZM-SPECT imaging, a radiopharmaceutical which la-
bels the postsynaptic D2 receptors and the discrimination be-
tween idiopathic PD and Parkinson-plus syndromes (multiple
system atrophy, progressive supranuclear palsy and cortico-
basal ganglia degeneration), is mentioned.
Key words: molecular imaging, movement disorders, PET,
SPECT, -123-DaTSCAN, I-1Z3-IB2M
Introduction
Parkinsons disease (PD) is a neurodegenerative disorder
characterized by progressive damage of the nigrostriatal dopa-
minergic neurons in the basal ganglia. The neurons projecting to
the putamen present the most severe impairment compared to
those innervating caudate nucleus. The result of this process is
the alteration of the neurochemical balance required for normal
motor function. Clinical symptoms (tremor, rigidity and bradyki-
nesia) occur when at least 50% of the dopaminergic cells are lost
[1]. Traditionally, PD is clinically diagnosed when two at least of
the above mentioned syndromes are present. Post-mortem exa-
mination in PD showed that the loss of dopaminergic cells is as-
sociated with depletion of striatal dopaminergic transporter
(DAT) [2].
Parkinsonian syndromes (PS) is a broader definition that en-
compasses other movement disorders whose symptoms resem-
ble PD and includes progressive supranuclear palsy (PSP), multi-
ple system atrophy (MSA) and corticobasal ganglia degeneration
(CBGD) [3].
The diagnosis of PD remains a clinical judgment based pri-
marily upon motor examination and the patients response to
L-dopa. Confusingly, the symptoms of PD or PS may also be expe-
rienced by individuals with essential tremor (ET), or as a result of
the use of certain medications, such as antipsychotics or calcium
channel blockers. ET is defined as an isolated postural/action trem-
or in otherwise neurological healthy person. Early differentiation
between these conditions is difficult, since in many cases a six
months evaluation of patients is mandatory to differentiate PD or
PS from ET. Despite the fact that there are definitions between PD
and ET, frequently final diagnosis is found wrong only after death.
It has been mentioned that up to 25% of patients initially diag-
nosed as PD, later having their diagnosis changed to ET [47].
In recent years, techniques that allow imaging of the dopam-
inegric system have been developed in order to help the clinical
diagnosis of PS. Such techniques are often based on assess-
ment of DAT density as a marker for dopaminergic nigrostriatal
neuron integrity [8]. Ioflupane, N-w -fluoropropyl-2b-carbomethoxy-
3b-(4-iodophenyl) nortropane, also called FP-CIT, belongs to
a group of compounds derived from cocaine that bind to the
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dopamine transporter (DAT). Introduction of the 123I radioactive la-
bel at the phenyl moiety further increased the binding affinity to the
DAT, whilst the iodine-carbon bond in this position is sufficiently
stable to resist deiodination in vivo. Further modifications of the
cocaine molecule likewise led to improved properties for single
photon emission tomography (SPET) imaging, 36 hours post injec-
tion of the radiopharmaceutical and increased selectivity of the DAT,
relative to binding to serotonin and norepinephrine transporters [9].
Imaging of the presynaptic nigrostriatal
dopaminergic system
In the early 1970s the successful application of 6-18F-fluoro-
L-3, 4-dihydroxyphenylalanine (18F-DOPA) for PET studies of the
nigrostriatal dopaminergic neurons has been reported [10].
18F-DOPA PET provides measurement of the structural as well as
the biochemical integrity of the dopaminergic neurons.
In the late 1980s studies have shown the use of radioligands
derived from cocaine in order to quantify nigrostriatal dopaminer-
gic neurons by means of SPET and PET (FP-CIT, b-CIT, CFT
(2b-carbomethoxy-3b-4fluorophenyl-tropane), IPT (N-3-iodopro-
pen-2-yl-2b-carbomethoxy-3b-4-fluorophenyl-tropane), 123I-altro-
pane, 11C-cocaine, 11C-methylphenidate, which are specific to the
binding sites [1114]. In addition, radiotracers for the vesicular
monoamine transporter derived from tetrabenazine have been
introduced to visualize dopaminergic neurons [15] (Table 1).
Imaging of dopamine D2 receptors
Dopamine acts in the central nervous system through activa-
tion of dopamine receptors, which are present in the pre- and the
postsynaptic cleft. Five different subtypes of dopamine receptors
have been described, but they actually fall into two classes: D1
type (D1, D5) and D2 type (D2, D3, D4), with the concentration of D1
and D2 receptors being higher than other types (16). Attention is
paid only to radiotracers for the dopamine D2 receptors, localized
in majority postsynaptically, since specific imaging studies of them
have been shown to be of value for the differential diagnosis of
parkinsonism. The most widely used radiotracers for imaging of
these receptors for SPECT studies are the dopamine receptors
antagonists iodobenzamine (I-123-IBZM) and I-123-epidepride [17,
18] and for PET studies 11C-raclopride and 18F-N-methylspiroperi-
dol [19, 20] (Table 1).
Molecular imaging in Parkinsons disease
Parkinsons disease (PD) is accounting up to 85% of all cau-
ses of parkinsonism [21]. PD is characterized by degeneration of
the nigrostriatal dopaminergic projection, leading to loss of dopa-
mine and dopamine transporters to the striatum [22].
PET studies with 18F-DOPA performed in patients with PD, have
shown reduction of the radiopharmaceutical uptake to the stria-
tum, more prominent in the putamen than in the caudate nucleus
[22]. In patients with early PD uptake was asymmetric (reduction
more prominent to the contra-lateral of the affected site) and cor-
related with the disease severity [2325].
The challenge of molecular (SPET and PET) imaging is the
early (preclinical) diagnosis of PD, since that by the time clinical
diagnosis has been made, about 5060% of dopaminergic neu-
rons projecting to the striatum have been already lost [1, 26].
Imaging with 123I-b-CIT has been performed to asymptomatic
relatives of PD patients with an increased risk of developing PD,
selecting 25 (10%) individuals being the worst smellers [2728].
An abnormal reduction of unilateral or bilateral dopamine trans-
mitter binding has been found in 4 (25%) of them and two of these
hyposmic PD relatives developed clinical parkinsonism. In addi-
tion, two hyposmic subjects had a unilateral reduction of puta-
men to caudate binding ratio and an increased putamen asym-
metry index, respectively. Other clinical conditions, such as neu-
ro-cognitive dysfunctions and visuo-motor abnormalities, often
precede the onsets of the typical PD motor signs and in such
cases 123I-FP-CIT might represent a useful tool for detecting the
dopaminergic deficit at a pre-clinical stage, so allowing the com-
mencement of neuroprotective treatment, aimed at slowing the
progressive degeneration of dopaminergic neurons [27, 2930].
Other authors have mentioned that in early PD patients, who
were drug-naïve, binding ratios were 35% for the putamen and
55% for the caudate nuclei, compared with normal individuals [31
33]. These data indicate that molecular imaging with 123I-ioflu-
pane is a sensitive marker of the degree of the dopaminergic de-
generation in PD, correlated with the severity of the disease. It has
also been mentioned that uptake of the radiolabelled compound in
drug-naïve patients is bilaterally reduced, so this technique is able
to detect PD patients in a preclinical stage [34]. Finally, a high test/
/pretest reproducibility of 123I-b-CIT SPECT imaging was found [35].
In a more recent study Filippi et al. have postulated that in de
novo hemi-PD patients at an early stage (Hoehn and Yahr stage I)
with unilateral symptoms and preclinical dopamine transporter loss
in the ipsilateral striatal binding, imaging with 123I-FP-CIT detects a
bilateral dopaminergic deficit [36] (Figure 1). According to these
data, semi-quantitative analysis can be used to diagnose PD at
an early stage and to identify individuals developing bilateral
dopaminergic deficit. Similar data have been postulated by Marek
et al in a small series of patients [37].
PET studies with cocaine analogues labeled with 11C, allow to
screen for striatal, orbitofrontal and amygdalar presynaptic dopam-
inergic cell loss in PD patients. It has been also mentioned that
putaminal and orbitofrontal b-CFT binding levels are positively
correlated with motor and mentation scores respectively, of the
Unified Parkinsons Disease Rating Scale [38[. PET in PD using
11C or 18F-labelled CFT as a tracer for the dopamine transporter
can differentiate controls from patients with mild PD [39, 40].
Table 1. Radiopharmaceuticals commonly used for SPET and PET
imaging of presynaptic dopamine transporters, vesicular transporters
and post-synaptic dopamine D2 receptors
Presynaptic dopamine Vesicular Postsynaptic
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To study the influence of age and gender in human volun-
teers, Lavalaye et al have performed SPET study with 123I-FP-CIT
in 45 normal individuals (23 males plus 22 females). Specific to
non-specific striatal binding of the radiopharmaceutical seemed
to decrease with age and females were found to have significant-
ly higher 123I-FP-CIT binding ratios than males [41].
Other authors have published data according to which, spe-
cific to non-specific ratio of 123I-FP-CIT is a robust measure of PD
severity correlating with duration of disease. Variability in uptake
values suggest that factors others than nigrostriatal degeneration
may contribute to disease severity. Correlation of uptake of
123I-FP-CIT with bradykinesia but not with tremor is possible to
indicate an origin for tremor outwith the dopamine transporter sys-
tem [42]. According to these data, 123I-FP-CIT SPECT offers sig-
nificant potential in defining the nigrostriatal changes in PD.
SPECT imaging with 123I-b-CIT could not visualize differences
of the radiopharmaceutical uptake at the level of the striatum be-
tween 113 patients with PD, 9 with MSA and 4 with PSP [43].
Interestingly, El Fakhri et al, have postulated data, concerning the
differential diagnosis between PD and MSA, based on SPECT stud-
ies with 123I-FP-CIT and cerebral blood flow (CBF) with Tc-99m-
-ECD (44). Binding potential (BP) was significantly lower in PD (53%
reduction in caudate nucleus and 59% in the putamen) and MSA
(26% in caudate nucleus and 20% in putamen) compared to nor-
mal controls. BP has been found to be reduced in PD compared
to MSA in the caudate nucleus (36%) and putamen (49%). In ad-
dition, CBF was significantly reduced in MSA patients in caudate
nucleus (28%) and nucleus lentiformis (18%), compared to nor-
mal controls, whilst there were not any significant CBF differences
between PD patients and controls. Other studies of DAT uptake
have shown similar differences between MSA and PD [45], whilst
Messa et al have mentioned that uptake of 123I-b-CIT in the head
of the caudate has shown a greater reduction in 5 PSP patients
compared to 13 PD cases [46]. However, between-group overlap
was too large to allow differentiation between these diseases on
an individual basis.
The clinical benefit of molecular
imaging in movement disorders
Patients with ET present a postural tremor with or without
a kinetic tremor, involving the upper limbs. PD is characterized by
resting tremor, rigidity, bradykinesia and postural instability [1, 47].
Elderly individuals with ET may also present rest tremor and mild
parkinsonian features and this may lead to difficulties in the differ-
ential diagnosis between ET and PD [48]. Diagnosis of PD based
only on clinical assessment seems to have a limited accuracy.
It has been postulated that from 402 patients initially clinically di-
agnosed as parkinsonism, only 299 of them (74%) were confirmed
as PS after further evaluation applying recommended clinical di-
agnostic criteria. Of the remaining 103 subjects with a revised
diagnosis, 50 (48%) of them were finally diagnosed as ET, 37 (36%)
as vascular parkinsonism and 16 (16%) as Alzheimers disease [5].
Rajput et al have reported that 2435% of initial PD diagnoses
made by general neurologists were incorrect when examined by
autopsy. In the same study, it has been mentioned that when cor-
relation between clinical impression and subsequent pathology is
performed, only 7580% agreement is achieved [49]. In a study
enrolling 800 PD patients at an early (H & Y 1 or 2) stage, diag-
nosed by PD experts, after a 6-year follow-up, only 65 (8.1%) of
them did not have PD according to the study criteria [6].
SPECT and PET studies have shown normal uptake of the
radiopharamaceutical (123I-b-CIT and 18F-DOPA respectively) at the
level of the striatum, compatible with intact nigrostriatal dopamin-
ergic neurons in patients with ET [50, 51] (Figure 2).
A multicentre trial has been performed by the 123I-FP-CIT study
group across six centres in Europe in order to compare the stria-
tal uptake of DaTSCAN in patients with PS to that in patients with
benign ET. PS was defined as either PD, MSA and PSP [52]. At
each of six centres the investigator assessed the acquired
DaTSCAN images for their own subjects, blinded to the subjects
clinical diagnosis and this process was termed as the institution-
al read. Centrally standardized scans were assessed by a panel
of five investigators who were also blind to the subjects clinical
Figure1. Patient with PD (H&Y stage I). Figure 2. Patient with ET.
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diagnosis and who separately judged the scans to be visually
normal or abnormal and this process was defined as the blinded
panel read. According to the institutional read sensitivity of the
method was 97.5%, specificity 100%, positive predictive value
100% and negative predictive value 87.1%. The results for the
blinded panel read were 95%, 93%, 99% and 76% respectively.
These results reflect some differences of opinion between the two
groups of readers, but overall variations from centre-to-centre were
minimal and images from different SPECT instruments were
deemed to be equivalent. This study demonstrates the effective-
ness of DaTSCAN-SPECT in differentiating between the two pa-
tient (PS and ET) groups. Other functional imaging studies using
only quantitative analysis in assessing striatal uptake, have men-
tioned that in 25 patients with PD, the specific:nonspecific uptake
ratio of  123I-b-CIT was significantly lower than in ET or healthy volun-
teers [53]. Booij et al using 123I-FP-CIT in a group of patients with
inconclusive forms of parkinsonism and performing clinical fol-
low-up of these patients 24 years after imaging, have concluded
that the positive predictive value of this technique is very high [54].
In another study with 123I-Ioflupane SPECT imaging in 43 individu-
als, 95.5% (21/22) of patients were correctly diagnosed as pre-
synaptic PS, whilst all patients (22/22) with ET were correctly eval-
uated with the molecular imaging method [55].
The clinical impact of dopamine transporter SPECT imaging
using 123I-Ioflupane, on the diagnosis and management of patients
with uncertain parkinsonian syndromes has been studied by
Catafau and Tolosa [56]. In 36% of patients with presynaptic PS
and 54% with non-presynaptic PS, imaging results were not con-
sistent with the initial diagnosis. Initial diagnosis was changed af-
ter SPECT study in 52% of the patients, 42% with an initial diagno-
sis of presynaptic PS and 54% with a diagnosis of non-presynap-
tic PS. After imaging, 76% of inconclusive patients (n = 19) were
reclassified as presynaptic (n = 14) or non-presynaptic PS (n = 5),
leaving 6 patients in the inconclusive category; 16 patients classi-
fied initially as presynaptic or non-presynaptic PS were reclassi-
fied as inconclusive after SPECT imaging review. After this review,
12 patients changed from presynaptic PS to inconclusive (75%
with normal image) and 4 patients changed from non-presynap-
tic PS to inconclusive (75% with abnormal images). Changes to
planned clinical management after 123I-Ioflupane SPECT imaging
were recorded in 72% of the cases, changes involving therapy in
most cases (46%), mainly because new therapy was initiated.
Another impact in management was either shortening or length-
ening visit intervals during follow-up (21%). This study shows that
123I-Ioflupane SPECT imaging had an effect in directing further
investigations and therapeutic intervention in patients with uncer-
tain parkinsonian syndromes.
Juvenile-onset dystonia that improves after levodopa admin-
istration may occur in both dopa-responsive dystonia (DRD) and
juvenile parkinsonism (JP), similar conditions with different prog-
noses and management goals. It has been postulated that nor-
mal striatal uptake of the dopamine transporter ligand FP-CIT with
the SPECT method is mentioned in a clinically atypical case of
DRD, in contrast to the reduced uptake observed in JP [57].
In cases of schizophrenia, functional changes in the dopa-
minergic system are not likely to be reflected in a change of the
dopamine transporter density and this does not seemed to be
altered by anti-psychotic medication [58]. In addition, schizophren-
ic patients with tardive dyskinesia, studied with 123I-FP-CIT SPECT,
performed no change in striatal dopamine transporter density [59].
Costa and colleagues have shown that severe DAT loss
exists in both the caudate nuclei (CN) in patients with PD and in
patients with Lewy-body dementia (DLB), as well as in the puta-
men. DAT loss in the CN was more severe in DLB than in PD,
particularly in the left hemisphere [60]. In patients with Alzheimers
disease, uptake of the radiopharmaceutical did not differ signifi-
cantly from that of normal volunteers (Figure 3). The left hemi-
sphere predominance of DAT loss in DLB subjects may explain
the psychotic component of their clinical presentation and this
may help to guide antipsychotic treatment. Walker et al have pos-
tulated that patients with DLB and PD showed significantly lower
uptake of the radiopharmaceutical in all striatal areas than con-
trols and patients with AD (Figure 4). There were no significant
differences in binding measures between patients with AD on the
ipsilateral and contralateral caudate, the ipsilateral and contrala-
teral anterior putamen, and the ipsilateral posterior putamen, but
patients with AD had lower binding than controls in the contralat-
eral posterior putamen [61]. Similar data have published Costa et
al, who have mentioned that in cases of DLB there is a marked
reduction of tracer uptake in the striatum of both hemispheres
Figure 3. Normal volunteer (Dopamine transporter availability with I-123-
FP-CIT) 30-year-old female.
Figure 4A. Normal patient (79-year-old; B. Patient with PD (76-year-old
men).
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that is marked in both putamen and caudate nucleus, whereas in
AD the appearance is within normal limits. The DLB appearance
is similar to that of PD, however there is a trend for lower caudate
uptake in DLB  than PD and lower posterior/caudal putamen up-
take in PD (Figure 5) than in DLB (Figure 6) [62]. Walker et al.
have also shown differences PD and DLB groups in the pattern of
striatal dopaminegic dysfunction. The mean caudate/putamen ratio
in DLB did not differ from that of controls, whilst the mean cau-
date/putamen ratio of the PD group was higher than that of the
control group, explaining some of the clinical differences between
DLB and PD [63]. In another study it has been also suggested
that functional (SPECT) imaging of the nigrostriatal dopamine path-
way helps to distinguish DLB from Alzheimers disease during life
[64].
Clinically, there are difficulties in the follow-up of PD progres-
sion, since it has to be about 1517% degradation of the presy-
naptic dopaminergic neurons to evaluate this [1]. Sang EK and
his colleagues have examined the correlation of SPECT measures
of 123I-b-CIT binding to DA and 5-HT transporters with symptom
severity in cases of PD. The authors found a significant correla-
tion of SPECT measurements of 123I-b-CIT binding to DA trans-
porters with motor severity and this can serve as an in vivo indica-
tor of disease severity in PD, with potential utility in the serial mon-
itoring of disease progression. In contrast, the radiopharmaceuti-
cal binding to serotonin (5-HT) transporters in the hypothalamic/
/midbrain region was not correlated with measures of motor and
non-motor severity [65].
In Gilles de la Tourette syndrome (GTS), which is character-
ized by the presence of multiple motor and one or more vocal tics
and in some cases by behavioral disorders [66], a SPECT study
with 123I-FP-CIT in ten neuroleptic naïve patients, has shown higher
striatal binding of the radiopharmaceutical in comparison with age-
and gender-matched control subjects [67]. However, according
to the authors, it appears that behavioral and psychiatric symp-
toms in GTS are not directly related measurable abnormalities in
striatal DAT activity.
Differential diagnosis between Parkinsons
disease and parkinsonian-plus syndromes
with imaging of D2 receptors
Post-mortem studies have practically shown no changes in
numbers of striatal dopamine D2 receptors in PD [68]. Ichise et al.
have postulated up-regulation of the striatal D2 post-synaptic recep-
tors in L-DOPA untreated patients with PD, with 123I-IBF study [69].
Other PET and SPECT studies have mentioned normal or increased
dopamine D2 dopamine receptor binding in patients with PD [70,
71]. The last study [71], was evaluating patients with de novo
parkinsonism in whom imaging with I-123-IBZM was performed
before the initiation of dopaminergic medication. During clinical
follow-up none of the patients with reduced I-123-IBZM binding
showed a positive response to dopaminergic medication and
therefore, reduced I-123-IBZM binding is likely to exclude
a diagnosis of PD early in the course of disease.
In another study performed by Hierholzer with 123I-IBZM, specif-
ic striatal D2 receptor binding was significantly lower in patients with
parkinsonian-plus syndromes compared to patients with PD [72].
During the follow-up, patients with PD showed a constant specific
striatal dopamine D2 receptor binding, in contrast with patients
with parkinsonian plus syndromes who revealed a further decline
of striatal dopamine D2 receptor binding during follow-up. In clinical
practice the differential diagnosis between idiopathic PD and Par-
kinson-plus syndromes seems to be of value, because in the latter
there is a lack of response to levodopa therapy. The presence of
other, non-parkinsonian neurological signs, suggests Parkinsonian-
plus syndromes, as well as, no response to levodopa therapy. Be-
cause of the similarity of the hypokinetic-rigid syndromes in PD to
that in Parkinson-plus syndromes, it is difficult in some cases to
discriminate between them. In early, mono-symptomatic cases with
only parkinsonism present, IBZM-SPECT is helpful in this discrimi-
nation. Decreased binding of the radiopharmaceutical to the stria-
tum, indicates striatal cell loss rendering PD unlikely and suggest-
ing Parkinson-plus syndrome [7174]. IBZM-SPECT cannot dis-
criminate between the different Parkinson-plus syndromes.
Figure 6. Dementia with Levy body (72-year-old men).Figure 5. Patient with vascular Parkinsonism (left putamen infarct) (56-year
old woman).
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It has been shown in various IBZM-SPECT studies that striatal
D2 binding is severely reduced in Huntingtons disease [75, 76].
However, in these cases, IBZM-SPECT seems to play a minor
role because of the major advantage of genetic diagnostic tests.
Conclusions
According to all these reviewed data, molecular imaging with
SPECT and PET, seems to play a critical role in patients with move-
ment disorders. SPECT and PET imaging with cocaine analogues
(i.e.123I-FP-CIT, 18F-DOPA) which label the presynaptic dopamine
transporters, is useful in differentiating patients with idiopathic PD
or Parkinson-plus syndromes, from individuals presenting essen-
tial tremor, so unnecessary treatment with L-dopa is prevented. In
addition molecular imaging plays a major role in the presymp-
tomatic diagnosis of PD, in the clinical impact of patients with
movement disorders and uncertain parkinsonian syndromes and
in the follow-up of them. Imaging of the nigrostriatal presynaptic
pathway is not able to discriminate patients with idiopathic PD
from those with Parkinson-plus syndromes. Imaging with I-123-IBZM,
a postsynaptic D2 ligand, is of value, since normal or increased
uptake of the radiopharmaceutical at the level of the striatum,
is compatible with PD.
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